These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29498553)

  • 1. OnabotulinumtoxinA treatment of moderate to severe glabellar lines in Chinese subjects after laser therapy: A prospective, open-label, noncomparative study.
    Wu Y; Lu Z; Xie Y; Zhang W; Chen X; Shi Y; Li Q; Halstead M; Rogers JD; Silberberg M
    J Cosmet Laser Ther; 2018 Oct; 20(5):278-286. PubMed ID: 29498553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, Efficacy, and Patient Satisfaction With OnabotulinumtoxinA for the Treatment of Upper Facial Lines in Japanese Subjects.
    Kawashima M; Harii K; Horiuchi Y; Seidman E; Lei X; Hopfinger R; Lee E
    Dermatol Surg; 2020 Apr; 46(4):483-490. PubMed ID: 31517663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OnabotulinumtoxinA for Treatment of Forehead and Glabellar Lines: Subject-Reported Satisfaction and Impact From a Phase 3 Double-Blind Study.
    Ogilvie P; Rivkin AZ; Dayan S; Yoelin SG; Weichman BM; Garcia JK
    Dermatol Surg; 2019 May; 45(5):689-699. PubMed ID: 31034447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Repeated OnabotulinumtoxinA Treatments in Subjects With Crow's Feet Lines and Glabellar Lines.
    Carruthers J; Rivkin A; Donofrio L; Bertucci V; Somogyi C; Lei X; Davis PG; Campo A; Beddingfield FC
    Dermatol Surg; 2015 Jun; 41(6):702-11. PubMed ID: 25993609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subject satisfaction with onabotulinumtoxinA treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure.
    Rivers JK; Bertucci V; McGillivray W; Muhn C; Rosen N; Solish N; Weichman BM; Wheeler S; Daniels SR; Gallagher CJ
    Dermatol Surg; 2015 Aug; 41(8):950-9. PubMed ID: 26218728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OnabotulinumtoxinA for Simultaneous Treatment of Upper Facial Lines: Subject-Reported Satisfaction and Impact From a Phase 3 Study.
    Rivkin AZ; Ogilvie P; Dayan S; Yoelin SG; Weichman BM; Garcia JK
    Dermatol Surg; 2020 Jan; 46(1):50-60. PubMed ID: 30829771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study.
    Wu Y; Fang F; Lai W; Li C; Li L; Liu Q; Lu J; Pang X; Sun J; Shi X; Picaut P; Prygova I; Andriopoulos B; Sun Q
    Aesthetic Plast Surg; 2023 Feb; 47(1):351-364. PubMed ID: 36536093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Patient Satisfaction for up to 6 Months With OnabotulinumtoxinA Treatment for Upper Facial Lines.
    Cohen JL; Fagien S; Ogilvie P; De Boulle K; Carruthers J; Cox SE; Kelly R; Garcia JK; Sangha S
    Dermatol Surg; 2022 Nov; 48(11):1191-1197. PubMed ID: 36342250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, Patient-Reported Outcomes, and Safety in Male Subjects Treated With OnabotulinumtoxinA for Improvement of Moderate to Severe Horizontal Forehead Lines.
    Keaney TC; Cavallini M; Leys C; Rossi A; Drinkwater A; Manson Brown S; Garcia JK; Mao C
    Dermatol Surg; 2020 Feb; 46(2):229-239. PubMed ID: 31343446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Pharmacodynamic Response, and Treatment Satisfaction With OnabotulinumtoxinA 40 U, 60 U, and 80 U in Subjects With Moderate to Severe Dynamic Glabellar Lines.
    Joseph JH; Maas C; Palm MD; Lain E; Glaser DA; Bruce S; Yoelin S; Cox SE; Fagien S; Sangha S; Maltman J; Lei X; Brin MF
    Aesthet Surg J; 2022 Oct; 42(11):1318-1327. PubMed ID: 35704394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OnabotulinumtoxinA (Botox) in the Treatment of Crow's Feet Lines in Japanese Subjects.
    Harii K; Kawashima M; Furuyama N; Lei X; Hopfinger R; Lee E
    Aesthetic Plast Surg; 2017 Oct; 41(5):1186-1197. PubMed ID: 28733805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 3 Study of OnabotulinumtoxinA Distributed Between Frontalis, Glabellar Complex, and Lateral Canthal Areas for Treatment of Upper Facial Lines.
    De Boulle K; Werschler WP; Gold MH; Bruce S; Sattler G; Ogilvie P; Street J; Larsen KE; Yushmanova I; Lei X; Lee E; Vitarella D; Mao C
    Dermatol Surg; 2018 Nov; 44(11):1437-1448. PubMed ID: 30096106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pooled Subject-Reported Outcomes From 2 Phase 3 Studies of OnabotulinumtoxinA for Simultaneous Treatment of Forehead and Glabellar Lines.
    Ogilvie P; Rivkin AZ; Dayan S; Yoelin SG; Larsen KE; Varon S; Garcia JK
    Dermatol Surg; 2020 Jul; 46(7):950-957. PubMed ID: 31567611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females.
    Carruthers A; Carruthers J; Said S
    Dermatol Surg; 2005 Apr; 31(4):414-22; discussion 422. PubMed ID: 15871316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study.
    Prager W; Bee EK; Havermann I; Zschocke I
    Clin Interv Aging; 2013; 8():449-56. PubMed ID: 23650444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forehead Line Treatment With OnabotulinumtoxinA in Subjects With Forehead and Glabellar Facial Rhytids: A Phase 3 Study.
    Fagien S; Cohen JL; Coleman W; Monheit G; Carruthers J; Street J; Larsen KE; Yushmanova I; Lei X; Lee E; Vitarella D; Mao C
    Dermatol Surg; 2017 Dec; 43 Suppl 3():S274-S284. PubMed ID: 33065953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
    Prager W; Rappl T
    J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated OnabotulinumtoxinA Treatment of Glabellar Lines at Rest Over Three Treatment Cycles.
    Carruthers A; Carruthers J; Fagien S; Lei X; Kolodziejczyk J; Brin MF
    Dermatol Surg; 2016 Sep; 42(9):1094-101. PubMed ID: 27427996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
    Rzany BJ; Ascher B; Avelar RL; Bergdahl J; Bertucci V; Bodokh I; Carruthers JA; Cartier H; Delmar H; Denfeld R; Gross JE; Heckmann M; Hedén P; Hilton S; Inglefield C; Ogilvie P; Sattler G; Sebastian M; Solish N; Swift A; Trévidic P
    Aesthet Surg J; 2020 Mar; 40(4):413-429. PubMed ID: 30951166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, Patient-Reported Outcomes, and Safety for Millennial Subjects Treated With OnabotulinumtoxinA for Moderate to Severe Horizontal Forehead Lines.
    Palm MD; Few J; Patel T; Safa M; Drinkwater A; Mao C; Garcia JK
    Dermatol Surg; 2020 May; 46(5):653-661. PubMed ID: 31625954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.